Granted Patent
B2
US 12,642,832 · App. 19/235,000 · Granted Jun 2, 2026
Oncolytic virus therapy
Inventors:
ZongSheng Guo (Wexford, PA); David Bartlett (Pittsburgh, PA); Zuqiang Liu (Wexford, PA); Mathilde Feist (Pittsburgh, PA)
View Patent ↗
Loading inventors, assignments & file history…
Abstract
The presently disclosed subject matter relates to tumor infiltrated T cells induced by oncolytic virus (“OV-induced T cells”), methods of making and using said OV-induced T cells for an adoptive T-cell therapy. The presently disclosed subject matter further relates to oncolytic viruses and armed oncolytic viruses, methods of making and using said oncolytic viruses, as well as pharmaceutical compositions and kits comprising said oncolytic viruses.
Claims (19)
1 . A method of treating a subject suffering from cancer, wherein the cancer is melanoma, wherein said method comprises:
(a) administering, to the subject, an effective amount of an oncolytic virus to induce the infiltration of one or more T cells into the cancer, wherein the oncolytic virus is a herpes simplex virus (HSV) and the HSV comprises a nucleic acid encoding granulocyte macrophage colony-stimulating factor (GM-CSF); and
(b) following step (a), administering, to the subject, an effective amount of ex vivo expanded T cells that were expanded ex vivo from one or more T cells isolated from the cancer of the subject, wherein the one or more T cells were isolated after step (a).
2 . The method of claim 1 , wherein the subject is a subject that was treated with a cancer therapy before step (a).
3 . The method of claim 1 , further comprising treating the subject with a cancer therapy.
4 . The method of claim 1 , further comprising providing to the subject one or more exogenous cytokines.
5 . The method of claim 4 , wherein the one or more exogenous cytokines comprises exogenous IL-2.
6 . The method of claim 1 , wherein the oncolytic virus is Talimogene laherparepvec (T-VEC).
7 . The method of claim 2 , wherein the cancer therapy comprises an immune checkpoint inhibitor.
8 . The method of claim 7 , wherein the immune checkpoint inhibitor comprises an anti-PD1 antibody, anti-PD-L1 antibody, or anti-CTLA-4 antibody.
9 . The method of claim 3 , wherein the cancer therapy comprises an immune checkpoint inhibitor.
10 . The method of claim 9 , wherein the immune checkpoint inhibitor comprises an anti-PD1 antibody, anti-PD-L1 antibody, or anti-CTLA-4 antibody.
11 . The method of claim 1 , wherein the cancer is metastatic melanoma.
12 . The method of claim 1 , wherein the oncolytic virus is administered via intratumoral injection.
13 . The method of claim 1 , wherein the oncolytic virus is administered at between about 1×10 5 pfu and 1×10 8 pfu per dose.
14 . The method of claim 9 , wherein the immune checkpoint inhibitor is administered one or two of before, in combination with, or after administration of the oncolytic virus.
15 . The method of claim 9 , wherein the immune checkpoint inhibitor is administered one or two of before, in combination with, or after administration of the tumor-infiltrated T cells.
16 . The method of claim 15 , wherein the immune checkpoint inhibitor is an anti-PD-1 antibody.
17 . The method of claim 1 , wherein following step (a) but prior to step (b), the subject is administered lymphodepletion therapy.
Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Apr 9, 2026
From: GUO, ZONG SHENG; BARTLETT, DAVID; LIU, ZUQIANG; FEIST, MATHILDE
To: UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
Reel/Frame 074326/0275 →
Continuity (3)
Division
16482623
Provisional Application
62454526
· Feb 3, 2017
References Cited (190)
US 6277368B1
· Hiserodt et al.
· 2001
[cited by applicant]
US 7208313B2
· McCart et al.
· 2007
[cited by applicant]
US 7264820B2
· Hiserodt et al.
· 2007
[cited by applicant]
US 8506947B2
· McCart et al.
· 2013
[cited by applicant]
US 20030105054A1
· Wagner et al.
· 2003
[cited by applicant]
US 20030170238A1
· Gruenberg et al.
· 2003
[cited by applicant]
US 20100303714A1
· Kirn
· 2010
[cited by applicant]
US 20150250837A1
· Nolin et al.
· 2015
[cited by applicant]
US 20160000842A1
· Song et al.
· 2016
[cited by applicant]
US 20170291934A1
· Reed et al.
· 2017
[cited by applicant]
US 20230002465A1
· Bartlett et al.
· 2023
[cited by applicant]
CA 2962099
· 2016
[cited by applicant]
CN 101912421
· 2010
[cited by applicant]
CN 105658795
· 2016
[cited by applicant]
CN 110267978
· 2019
[cited by applicant]
JP 2009507853
· 2009
[cited by applicant]
JP 2016512199
· 2016
[cited by applicant]
JP 2016527920
· 2016
[cited by applicant]
WO WO1999006544
· 1999
[cited by applicant]
WO WO2003017944
· 2003
[cited by applicant]
WO WO2008113078
· 2008
[cited by applicant]
WO WO2012142529
· 2012
[cited by applicant]
WO WO2014138314
· 2014
[cited by applicant]
WO WO2015027163
· 2015
[cited by applicant]
WO WO2016174200
· 2016
[cited by applicant]
WO WO2016070136
· 2016
[cited by applicant]
WO WO2016146894
· 2016
[cited by applicant]
WO WO2017044780
· 2017
[cited by applicant]
WO WO2017165464
· 2017
[cited by applicant]
WO WO2017201350
· 2017
[cited by applicant]
WO WO2018145033
· 2018
[cited by applicant]
WO WO2018213731
· 2018
[cited by applicant]
WO WO2020124274
· 2020
[cited by applicant]
Rosenberg (Current Opinion in Immunology 2009, 21:233-240).
[cited by examiner]
Senzer (Journal of Clinical Oncology, 2009, 27:5763-5771).
[cited by examiner]
Bommareddy (Am J Clin Dermatol. Feb. 2017 ; 18(1): 1-15. doi: 10.1007/s40257-016-0238-).
[cited by examiner]
Overwijk et al., “Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells,” The Journal of Experimental Medicine, Aug. 18, 2003, 198(4):569-580.
[cited by applicant]
Hamza T, Barnett JB, Li B. Interleukin 12 a key immunoregulatory cytokine in infection applications. Int J Mol Sci. Feb. 26, 2010; 11(3):789-806. doi: 10.3390/ijms11030789. PMID: 20479986; PMCID: PMC2869233. (Year: 2010…
[cited by applicant]
Abastado, “The next challenge in cancer immunotherapy: controlling T-cell traffic to the tumor,” Cancer Research, May 2012, 72(9):2159-2161.
[cited by applicant]
Abdi et al., “Free IL-12p40 Monomer Is a Polyfunctional Adaptor for Generating Novel IL-12-like Heterodimers Extracellularly,” J. Immunology, Jun. 15, 2014, 192(12):6028-6036.
[cited by applicant]
Alvarez-Breckenridge et al., “NK cells impede glioblastoma virotherapy through NKp30 and NKp46 natural cytotoxicity receptors,” Nat. Med., 2012, 18(12):1827-1834.
[cited by applicant]
Andtbacka et al., “Talimogene laherparepvec improves durable response rate in patients with advanced melanoma,” J. Clin. Oncol., Sep. 2015, 33(25):2780-8.
[cited by applicant]
Arai et al., “Design of the linkers which effectively separate domains of a bifunctional fusion protein,” Prot. Eng., Aug. 2001, 14(8):529-532.
[cited by applicant]
Atkins et al., “Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies,” Clin. Cancer Research, Mar. 1997, 3(3):409-417.
[cited by applicant]
Baluna et al., “Vascular leak syndrome: a side effect of immunotherapy,” Immunopharmacology, Oct. 1997, 37(2-3):117-32.
[cited by applicant]
Bartlett et al., “Oncolytic viruses as therapeutic cancer vaccines,” Mol. Cancer, Sep. 11, 2013, 12(1):103, 16 pages.
[cited by applicant]
Berraondo et al., “Revisiting Interleukin-12 as a Cancer Immunotherapy Agent,” Clin. Cancer Research, Jun. 15, 2018, 24(12):2716-2718.
[cited by applicant]
Bommareddy et al., “Integrating oncolytic viruses in combination cancer immunotherapy,” Nat. Rev. Immunology, Aug. 2018, 18(8):498-513.
[cited by applicant]
Bourgeois-Daigneault et al., “Neoadjuvant oncolytic virotherapy before surgery sensitizes triple-negative breast cancer to immune checkpoint therapy,” Sci. Transl. Medicine, Jan. 3, 2018, 10(422):eaao1641, 12 pages.
[cited by applicant]
Boyman et al., “Potential use of IL-2/anti-IL-2 antibody immune complexes for the treatment of cancer and autoimmune disease,” Expert Opin. Biol. Ther., Dec. 2006, 6(12):1323-1331.
[cited by applicant]
Boyman et al., “Selective stimulation of T cell subsets with antibody-cytokine immune complexes,” Science, Mar. 2006, 311(5769):1924-7.
[cited by applicant]
Boyman et al., “The role of interleukin-2 during homeostasis and activation of the immune system,” Nat. Rev. Immunol., Mar. 2012, 12(3):180-90.
[cited by applicant]
Brahmer et al., “Safety and activity of anti-PD-L1 antibody in patients with advanced cancer,” N. Engl. J. Medicine, Jun. 28, 2012, 366(26):2455-2465.
[cited by applicant]
Brandacher et al., “Prognostic value of indoleamine 2, 3-dioxygenase expression in colorectal cancer: effect on tumor-infiltrating T cells,” Clin. Cancer Res., Feb. 2006, 12(4):1144-51.
[cited by applicant]
Cao et al., “Interleukin 12 stimulates IFN-gamma-mediated inhibition of tumor-induced regulatory T-cell proliferation and enhances tumor clearance,” Cancer Research, Nov. 15, 2009, 69(22):8700-8709.
[cited by applicant]
Cervera-Carrascon et al., “TNFa and IL-2 armed adenoviruses enable complete responses by anti-PD-1 checkpoint blockade,” Oncoimmunology, Apr. 9, 2018, 7(5):e1412902, 12 pages.
[cited by applicant]
Chatterjee et al., “The intricate role of CXCR4 in cancer,” Advances in Cancer Research, Jan. 2014, 124:31-82.
[cited by applicant]
Chen et al., “Elements of cancer immunity and the cancer-immune set point,” Nature, Jan. 18, 2017, 541:321-330.
[cited by applicant]
Chen et al., “Fusion protein linkers: property, design and functionality,” Adv. Drug Deliv. Rev., Oct. 2013, 65(10):1357-69.
[cited by applicant]
Chen et al., “Oncology meets immunology: the cancer-immunity cycle,” Immunity, Jul. 25, 2013, 39(1):1-10.
[cited by applicant]
Chiocca et al., “Oncolytic viruses and their application to cancer immunotherapy,” Cancer Immunol. Res., Apr. 2014, 2(4):295-300.
[cited by applicant]
Choi et al., “IL-12p35 Inhibits Neuroinflammation and Ameliorates Autoimmune Encephalomyelitis,” Front. Immunol., Oct. 2017, 8:1258.
[cited by applicant]
Chon et al., “Tumor Microenvironment Remodeling by Intratumoral Oncolytic Vaccinia Virus Enhances the Efficacy of Immune-Checkpoint Blockade,” Clin. Cancer Research, Mar. 1, 2019, 25(5):1612-1623.
[cited by applicant]
Cohen, “IL-12 deaths: explanation and a puzzle,” Science, Nov. 10, 1995, 270(5238):908.
[cited by applicant]
Colombo et al., “Interleukin-12 in anti-tumor immunity and immunotherapy,” Cytokine Growth Factor Reviews, Apr. 2002, 13(2):155-168.
[cited by applicant]
Dennis et al., Current status of IL-10 and regulatory T-cells in cancer, Curr. Opin. Oncol., Nov. 2013, 25(6):637.
[cited by applicant]
Downs-Canner et al., “Phase 1 Study of Intravenous Oncolytic Poxvirus (vvDD) in Patients With Advanced Solid Cancers,” Mol. Therapy, Aug. 2016, 24(8):1492-1501.
[cited by applicant]
Efremova et al., “Targeting immune checkpoints potentiates immunoediting and changes the dynamics of tumor evolution,” Nat. Communications, Jan. 2, 2018, 9(1):32, 13 pages.
[cited by applicant]
Epstein et al., “Identification of a protein fragment of interleukin 2 responsible for vasopermeability,” J Natl Cancer Inst, May 2003, 95(10):741-749.
[cited by applicant]
Essentials of Glycobiology, 2nd ed., Varki et al. (eds.), 2009, Chapter 11, 27 pages.
[cited by applicant]
Extended European Search Report in European Appln. No. 20889840.3, dated Sep. 8, 2023, 12 pages.
[cited by applicant]
Feig et al., “Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer,” Proc. Natl. Acad. Sci. USA, 2013, 110(50):20212-20217.
[cited by applicant]
Feist et al., “Oncolytic virus promotes tumor-reactive infiltrating lymphocytes for adoptive cell therapy,” Cancer Gene Ther., Jul. 7, 2020, 14 pages.
[cited by applicant]
Ferguson et al., “Chapter 11: Glycosylphosphatidyl Anchors” Glycobiology, 2nd Edition, Varki et al. (ed)., Cold Spring Harbor Press, 2009, pp. 143-161.
[cited by applicant]
Fortin et al., “NK cell response to vaccinia virus is regulated by myeloid-derived suppressor cells,” J. Immunology, Aug. 15, 2012, 189(4):1843-1849.
[cited by applicant]
Fridman et al., “The immune contexture in human tumours: impact on clinical outcome,” Nat. Rev. Cancer, Apr. 2012, 12(4):298-306.
[cited by applicant]
Fukunaga et al., “CD8+ tumor-infiltrating lymphocytes together with CD4+ tumor-infiltrating lymphocytes and dendritic cells improve the prognosis of patients with pancreatic adenocarcinoma,” Pancreas, Jan. 2004, 28(1):e…
[cited by applicant]
Gajewski, “The Next Hurdle in Cancer Immunotherapy: Overcoming the Non-T-Cell-Inflamed Tumor Microenvironment,” Semin. Oncology, Aug. 2015, 42(4):663-671.
[cited by applicant]
Galian et al., “Efficient glycosylphosphatidylinositol (GPI) modification of membrane proteins requires a C-terminal anchoring signal of marginal hydrophobicity,” J. Biol. Chem., May 2012, 287(20):16399-409.
[cited by applicant]
Galon et al., “Type, density, and location of immune cells within human colorectal tumors predict clinical outcome,” Science, Sep. 2006, 313(5795):1960-4.
[cited by applicant]
Gao et al., “Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection,” J. Clin. Oncol., Jun. 2007, 25(18):2586-93.
[cited by applicant]
Gao et al., “Overexpression of PD-L1 significantly associates with tumor aggressiveness and postoperative recurrence in human hepatocellular carcinoma,” Clin. Cancer Res., 2009, 15(3):971-979.
[cited by applicant]
Ge et al., “Oncolytic vaccinia virus delivering tethered IL-12 enhances antitumor effects with improved safety,” J. Immunother. Cancer, Mar. 2020, 8(1):e000710, 8 pages.
[cited by applicant]
GenBank Accession No. AAH66254.1, “Interleukin 2 [
[cited by applicant]
GenBank Accession No. BC128562.1, “
[cited by applicant]
GenBank Accession No. CAA25742.1, “human interleukin 2 [
[cited by applicant]
GenBank Accession No. NM_000594.3, “
[cited by applicant]
Guo et al., “Oncolytic Immunotherapy: Conceptual Evolution, Current Strategies, and Future Perspectives,” Front. Immunology, May 15, 2017, 8:555, 15 pages.
[cited by applicant]
Guo et al., “Oncolytic immunotherapy: dying the right way is a key to eliciting potent antitumor immunity,” Front. Oncol., Apr. 2014, 4:74.
[cited by applicant]
Guo et al., “Oncolytic virotherapy: molecular targets in tumor-selective replication and carrier cell-mediated delivery of oncolytic viruses,” Biochim. Biophys. Acta., 2008, 1785(2):217-231.
[cited by applicant]
Guo et al., “The enhanced tumor selectivity of an oncolytic vaccinia lacking the host range and antiapoptosis genes SPI-1 and SPI-2,” Cancer Res., 2005 65(21):9991-9998.
[cited by applicant]
Guo et al., “Vaccinia virus-mediated cancer immunotherapy: cancer vaccines and oncolytics,” J. Immunother. Cancer, Jan. 9, 2019, 7(1):6, 21 pages.
[cited by applicant]
Heo et al., “Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer,” Nat Med., 2013, 19(3):329-336.
[cited by applicant]
Hodi et al., “Improved survival with ipilimumab in patients with metastatic melanoma,” N. Engl. J. Medicine, Aug. 19, 2010, 363(8):711-723.
[cited by applicant]
Hu et al., “Generation of low-toxicity interleukin-2 fusion proteins devoid of vasopermeability activity,” Blood, Jun. 2003, 101(12):4853-61.
[cited by applicant]
IGEM.org [online], “Designing Linkers: A comprehensive guide by the EPFL 2021 iGEM team,” 2021, retrieved on Oct. 28, 2024, retrieved from URL<https://static.igem.org/mediawiki/2021/d/de/T--EPFL--contribution--linkers.p…
[cited by applicant]
Ji et al., “Glycoinositol Phospholipid-anchored Interleukin 2 but not Secreted Interleukin 2 Inhibits Melanoma Tumor Growth in Mice 1 Supported by the Oncology Research Endowment of the Greenville Hospital System,” Mol.…
[cited by applicant]
Katre et al., “Chemical modification of recombinant interleukin 2 by polyethylene glycol increases its potency in the murine Meth A sarcoma model, ” Proc. Natl. Acad. Sci. USA, Mar. 1987, 84(6):1487-91.
[cited by applicant]
Kaufman et al., “Oncolytic viruses: a new class of immunotherapy drugs,” Nat. Rev. Drug Discov., Sep. 2015, 14(9):642-62.
[cited by applicant]
Keller et al., “Oncolytic viruses-immunotherapeutics on the rise,” J. Mol. Med., Aug. 4, 2016, 94(9):979-991.
[cited by applicant]
Kirn et al., “Enhancing poxvirus oncolytic effects through increased spread and immune evasion,” Cancer Res., Apr. 2008, 68(7):2071-5.
[cited by applicant]
Kobayashi et al., “FOXP3+ regulatory T cells and tumoral indoleamine 2,3-dioxygenase expression predicts the carcinogenesis of intraductal papillary mucinous neoplasms of the pancreas,” Pancreatology, 2010, 10(5):631-64…
[cited by applicant]
Kobayashi et al., “T1365 FOXP3+ Regulatory T Cells and Tumoral Indoleamine 2, 3-Dioxygenase Expression Predicts the Carcinogenesis of the Pancreas,” Gastroenterology, May 2010, 138(5):S-546.
[cited by applicant]
Kottke et al., “Subversion of NK-cell and TNFα immune surveillance drives tumor recurrence,” Cancer Immunol. Res., Nov. 2017, 5(11):1029-45.
[cited by applicant]
Kowalsky et al., “Superagonist IL-15-Armed Oncolytic Virus Elicits Potent Antitumor Immunity and Therapy That Are Enhanced with PD-1 Blockade,” Mol. Therapy, Oct. 3, 2018, 26(10):2476-2486.
[cited by applicant]
Lazear et al., “Targeting of IL-2 to cytotoxic lymphocytes as an improved method of cytokine-driven immunotherapy,” Oncoimmunology, Feb. 2017, 6(2):e1265721.
[cited by applicant]
Leach et al., “Enhancement of antitumor immunity by CTLA-4 blockade,” Science, Mar. 22, 1996, 271(5256):1734-1736.
[cited by applicant]
Lee et al., “Prognostic implications of type and density of tumour-infiltrating lymphocytes in gastric cancer,” Br. J. Cancer, 2008, 99(10):1704-1711.
[cited by applicant]
Lentsch et al., “Interleukin-10 inhibits interleukin-2-induced tumor necrosis factor production but does not reduce toxicity in C3H/HeN mice,” J. Leukoc. Biol., Jul. 1996, 60(1):51-7.
[cited by applicant]
Leonard et al., “Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-gamma production,” Blood, Oct. 1, 1997, 90(7):2541-2548.
[cited by applicant]
Létourneau et al., “IL-2/anti-IL-2 antibody complexes show strong biological activity by avoiding interaction with IL-2 receptor α subunit CD25,” Proc. Natl. Acad. Sci. USA, Feb. 2010, 107(5):2171-6.
[cited by applicant]
Levin et al., “Exploiting a natural conformational switch to engineer an interleukin-2 ‘superkine’,” Nature, Apr. 2012, 484(7395):529-33.
[cited by applicant]
Li et al., “Chemokine expression from oncolytic vaccinia virus enhances vaccine therapies of cancer,” Mol. Ther., Apr. 2011, 19(4):650-7.
[cited by applicant]
Liao et al., “Interleukin-2 at the crossroads of effector responses, tolerance, and immunotherapy,” Immunity, Jan. 2013, 38(1):13-25.
[cited by applicant]
Liu et al., “CXCL11-Armed oncolytic poxvirus elicits potent antitumor immunity and shows enhanced therapeutic efficacy,” Oncoimmunology, Mar. 2016, 5(3):e1091554.
[cited by applicant]
Liu et al., “Isolation of mouse tumor-infiltrating leukocytes by Percoll gradient centrifugation,” Bio-Protocol., 2013, 3(17).
[cited by applicant]
Liu et al., “Modifying the cancer-immune set point using vaccinia virus expressing re-designed interleukin-2,” Nat. Communications, Nov. 8, 2018, 9(1):4682, 9 pages.
[cited by applicant]
Liu et al., “Rational combination of oncolytic vaccinia virus and PD-L1 blockade works synergistically to enhance therapeutic efficacy,” Nat. Communications, Mar. 27, 2017, 8:14754, 12 pages.
[cited by applicant]
Lotze et al., “In vivo administration of purified human interleukin 2. II. Half life, immunologic effects, and expansion of peripheral lymphoid cells in vivo with recombinant IL 2,” J. Immunol., Oct. 1985, 135(4):2865-2…
[cited by applicant]
Mariathasan et al., “Tgfβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells,” Nature, Feb. 22, 2018, 554(7693):544-548.
[cited by applicant]
Martínez-Bosch et al., “Galectin-1 drives pancreatic carcinogenesis through stroma remodeling and Hedgehog signaling activation,” Cancer Res, 2014, 74(13):3512-3524.
[cited by applicant]
Matzinger, “The danger model: a renewed sense of self,” Science, Apr. 2002, 296(5566):301-5.
[cited by applicant]
Mayor et al., “Sorting GPI-anchored proteins,” Nature reviews Mol. Cell Biol., Feb. 2004, 5(2):110-20.
[cited by applicant]
McCart et al., “Systemic cancer therapy with a tumor-selective vaccinia virus mutant lacking thymidine kinase and vaccinia growth factor genes,” Cancer Res., Dec. 2001, 61(24):8751-7.
[cited by applicant]
Medof et al., “Cell-surface engineering with GPI-anchored proteins,” FASEB J., Apr. 1996, 10:574-586.
[cited by applicant]
Medzhitov et al., “Decoding the patterns of self and nonself by the innate immune system,” Science, Apr. 2002, 296(5566):298-300.
[cited by applicant]
Melder et al., “Pharmacokinetics and in vitro and in vivo anti-tumor response of an interleukin-2-human serum albumin fusion protein in mice,” Cancer Immunol. Immunother., Jun. 2005, 54(6):535-47.
[cited by applicant]
Nagarajan et al., “Glycolipid-anchored IL-12 expressed on tumor cell surface induces antitumor immune response,” Cancer Research, May 15, 2002, 62(10):2869-2874.
[cited by applicant]
Naik et al., “Intravenous and isolated limb perfusion delivery of wild type and a tumor-selective replicating mutant vaccinia virus in nonhuman primates,” Hum. Gene Therapy, Jan. 2006, 17(1):31-45.
[cited by applicant]
Nakakubo et al., “Clinical significance of immune cell infiltration within gallbladder cancer,” Br. J. Cancer, Nov. 2003, 89(9):1736-42.
[cited by applicant]
Nguyen et al., “Expansion and Characterization of Human Melanoma Tumor-Infiltrating Lymphocytes (TILs),” PLOS One, Nov. 2010, 5(11):e13940, 12 pages.
[cited by applicant]
Nomi et al., “Clinical Significance and Therapeutic Potential of the Programmed Death-1 Ligand/Programmed Death-1 Pathway in Human Pancreatic Cancer,” Clin. Cancer Res., Apr. 2007, 13(7):2151-2157.
[cited by applicant]
Pagès et al., “Effector memory T cells, early metastasis, and survival in colorectal cancer,” N. Engl. J. Med., Dec. 2005, 353(25):2654-66.
[cited by applicant]
Pan et al., “Cancer immunotherapy using a membrane-bound interleukin-12 with B7-1 transmembrane and cytoplasmic domains,” Molecular Therapy, May 2012, 20(5):927-37.
[cited by applicant]
Paulick et al., “The glycosylphosphatidylinositol anchor: a complex membrane-anchoring structure for proteins,” Biochemistry, Jul. 2008, 47(27):6991-7000.
[cited by applicant]
PCT International Preliminary Report on Patentability in International Appln. No. PCT/US2020/061578, mailed on Jun. 2, 2022, 8 pages.
[cited by applicant]
PCT International Preliminary Report on Patentability International Application No. PCT/US2018/016912 dated Aug. 6, 2019, 8 pages.
[cited by applicant]
PCT International Search Report and Written Opinion in International Application No. PCT/US2018/016912 dated May 10, 2018, 11 pages.
[cited by applicant]
PCT International Search Report and Written Opinion in International Appln. No. PCT/US2020/061578, mailed on Mar. 22, 2021, 11 pages.
[cited by applicant]
Pearl et al., “Oncolytic Virus-Based Cytokine Expression to Improve Immune Activity in Brain and Solid Tumors,” Mol. Ther. Oncolytics, Mar. 20, 2019, 13:14-21.
[cited by applicant]
Pelin et al., “Abstract #PR19: Utilizing novel oncolytic vaccinia virus for selective expression of immunotherapeutic payloads in metastatic tumors,” Cancer Immunol. Res., Apr. 2020, 8(4_supplement):PR19.
[cited by applicant]
Poutou et al., “Safety and antitumor effect of oncolytic and helper-dependent adenoviruses expressing interleukin-12 variants in a hamster pancreatic cancer model,” Gene Therapy, May 21, 2015, 22(9):696-706.
[cited by applicant]
Puskas et al., “Development of an Attenuated interleukin-2 Fusion Protein That Can Be Activated by Tumour-Expressed Proteases,” Immunology, Jun. 2011, 133(2):206-20.
[cited by applicant]
Qin et al., “Gene therapy for head and neck cancer using vaccinia virus expressing IL-2 in a murine model, with evidence of immune suppression,” Mol. Ther., Dec. 2001, 4(6):551-8.
[cited by applicant]
Quandt et al., “B7-h4 expression in human melanoma: its association with patients' survival and antitumor immune response,” Clin. Cancer Res., May 2011, 17(10):3100-11.
[cited by applicant]
Ribas et al., “Oncolytic virotherapy promotes intratumoral T cell infiltration and improves anti-PD-1 immunotherapy,” Cell, Sep. 2017, 170(6):1109-19.
[cited by applicant]
Ribas, “Adaptive Immune Resistance: How Cancer Protects from Immune Attack,” Cancer Discovery, Sep. 2015, 5(9):915-919.
[cited by applicant]
Rintoul et al., “A selectable and excisable marker system for the rapid creation of recombinant poxviruses,” PLoS one, 2011, 6(9):e24643.
[cited by applicant]
Rosenberg et al., “Adoptive cell transfer as personalized immunotherapy for human cancer,” Science, Apr. 3, 2015, 348(6230):62-68.
[cited by applicant]
Rosenstein et al., “Extravasation of intravascular fluid mediated by the systemic administration of recombinant interleukin 2,” J. Immunol., Sep. 1986, 137(5):1735-42.
[cited by applicant]
Russell et al., “Oncolytic virotherapy,” Nat. Biotechnol., Jul. 2012, 30(7):658.
[cited by applicant]
Saha et al., “Macrophage Polarization Contributes to Glioblastoma Eradication by Combination Immunovirotherapy and Immune Checkpoint Blockade,” Cancer Cell, Aug. 2017, 32(2):253-67.
[cited by applicant]
Samson et al., “Intravenous delivery of oncolytic reovirus to brain tumor patients immunologically primes for subsequent checkpoint blockade,” Sci. Transl. Medicine, Jan. 3, 2018, 10(422):eaam7577, 13 pages.
[cited by applicant]
Sathaiah et al., “Oncolytic poxvirus armed with Fas ligand leads to induction of cellular Fas receptor and selective viral replication in FasR-negative cancer,” Cancer Gene Ther., Mar. 2012, 19(3):192-201.
[cited by applicant]
Sharma et al., “Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy,” Cell, Feb. 9, 2017, 168(4):707-723.
[cited by applicant]
Siegal et al., “Cancer statistics,” CA Cancer J. Clin., Jan. 2014, 64(1):9-29.
[cited by applicant]
Simmons et al., “The Fcy receptor of natural killer cells is a phospholipid-linked membrane protein,” Nature, Jun. 1988, 333(6173):568-70.
[cited by applicant]
Smith et al., “PD-1 Blockade Following Isolated Limb Perfusion with Vaccinia Virus Prevents Local and Distant Relapse of Soft-tissue Sarcoma,” Clin. Cancer Research, Jun. 1, 2019, 25(11):3443-3454.
[cited by applicant]
Sun et al., “Regulation and Function of the PD-L1 Checkpoint,” Immunity, Mar. 20, 2018, 48(3):434-452.
[cited by applicant]
Takagi et al., “Dendritic cells, T-cell infiltration, and Grp94 expression in cholangiocellular carcinoma,” Hum. Pathol., Jul. 2004, 35(7):881-6.
[cited by applicant]
Tang et al., “PAMP s and DAMP s: signal 0s that spur autophagy and immunity,” Immunol. Rev., Sep. 2012, 249(1):158-75.
[cited by applicant]
The Free Dictionary [online], “Anchor,” 2022, retrieved on Nov. 1, 2022, retrieved from URL<www.thefreedictionary.com/anchoring>, 6 pages.
[cited by applicant]
Thorne et al., “Rational strain selection and engineering creates a broad-spectrum, systemically effective oncolytic poxvirus, JX-963,” J. Clin. Investig., Nov. 2007, 117(11):3350-8.
[cited by applicant]
Topalian et al., “Safety, activity, and immune correlates of anti-PD-1 antibody in cancer,” N. Engl. J. Medicine, Jun. 28, 2012, 366(26):2443-2454.
[cited by applicant]
Tugues et al., “New insights into IL-12-mediated tumor suppression,” Cell Death Differentiation, Feb. 2015, 22(2):237-246.
[cited by applicant]
Twumasi-Boateng et al., “Oncolytic viruses as engineering platforms for combination immunotherapy,” Nat. Rev. Cancer, Jul. 2018, 18(7):419-432.
[cited by applicant]
Uni Prot Accession No. O75015, “Low affinity immunoglobulin gamma Fc region receptor III,” dated Nov. 1, 1999, 9 pages.
[cited by applicant]
Vagner et al., “Rigid linkers for bioactive peptides,” Bioconjug. Chem., Nov.-Dec. 2006, 17(6):1545-1550.
[cited by applicant]
Van der Woude et al., “Migrating into the Tumor: a Roadmap for T Cells,” Trends Cancer, Nov. 2017, 3(11):797-808.
[cited by applicant]
Vazquez-Lombardi et al., “Potent antitumour activity of interleukin-2-Fc fusion proteins requires Fc-mediated depletion of regulatory T-cells,” Nat. Commun., May 2017, 8(1):1-2.
[cited by applicant]
Wang et al., “Re-designing Interleukin-12 to enhance its safety and potential as an anti-tumor immunotherapeutic agent,” Nat. Communications, Nov. 9, 2017, 8:1395, 15 pages.
[cited by applicant]
Written Opinion in International Application No. PCT/US2018/016912 dated May 10, 2018, 7 pages.
[cited by applicant]
Yadav et al., “Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing,” Nature, Nov. 26, 2014, 515:572-576.
[cited by applicant]
Yang et al., “Randomized study of high-dose and low-dose inter leukin-2 in patients with metastatic renal cancer,” J. Clin. Oncol., Aug. 2003, 21(16):3127.
[cited by applicant]
Zamarin et al., “Intratumoral modulation of the inducible co-stimulator ICOS by recombinant oncolytic virus promotes systemic anti-tumour immunity,” Nat. Communications, Feb. 13, 2017, 8:14340, 14 pages.
[cited by applicant]
Zamarin et al., “Localized oncolytic virotherapy overcomes systemic tumor resistance to immune checkpoint blockade immunotherapy,” Sci. Transl. Medicine, Mar. 5, 2014, 6(226):226ra232, 12 pages.
[cited by applicant]
Zeh et al., “First-in-man study of western reserve strain oncolytic vaccinia virus: safety, systemic spread, and antitumor activity,” Mol. Therapy, Jan. 2015, 23(1):202-214.
[cited by applicant]
Zhang et al., “Eradication of solid human breast tumors in nude mice with an intravenously injected light-emitting oncolytic vaccinia virus,” Cancer Res., Oct. 2007, 67(20):10038-46.
[cited by applicant]
Zhang et al., “Tumor-infiltrating lymphocytes genetically engineered with an inducible gene encoding interleukin-12 for the immunotherapy of metastatic melanoma,” Clin. Cancer Research, May 15, 2015, 21(10):2278-2288.
[cited by applicant]
Zou et al., “PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations,” Sci. Transl. Medicine, Mar. 2, 2016, 8(328):328rv324.
[cited by applicant]
Zou, “Immunosuppressive networks in the tumour environment and their therapeutic relevance,” Nat. Rev. cancer, Apr. 2005, 5(4):263-74.
[cited by applicant]